Views on Methods for Monitoring Recombinant Factor VIIa in Inhibitor Patients

Seminars in Hematology

Volumn 41, Issue 1 SUPPL. 1, 2004, Pages 51-54

  Key, Nigel S ^a   Nelsestuen, Gary L ^a  

^a Mayo Building ^*

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BLOOD CLOTTING; CLINICAL FEATURE; CONFERENCE PAPER; CORRELATION ANALYSIS; HEMOSTASIS; HUMAN; LABORATORY TEST; PATIENT MONITORING; PRIORITY JOURNAL; REPRODUCIBILITY; THROMBOCYTE FUNCTION;

EID: 0842320986     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2003.11.011     Document Type: Conference Paper

References (24)

1. Allen G, Hoffman M, Monroe DM: Manipulation of prothrombin concentration improves response to high dose factor VIIa in a cell-based model of hemophilia. Presented at the XIX Congress of the International Society on Thrombosis and Haemostasis, Birmingham, UK, July 12-18, 2003
2. Butenas S, Brummel KE, Branda RF, et al: Mechanism of action of factor VIIa-dependent coagulation in hemophilia blood. Blood 99:923-930, 2002
3. Carr ME Jr, Martin EJ, Kuhn JG, et al: Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion. Thromb Haemost 89:803-811, 2003b
4. Carr ME Jr: Development of platelet contractile force as a research and clinical measure of platelet function. Cell Biochem Biophys 38:55-78, 2003a
5. Galan AM, Tonda R, Altisent C, et al: Recombinant factor VIIa (NovoSeven®) restores deficient coagulation: experience from an ex vivo model. Semin Hematol 38:10-14, 2001 (suppl 12)
6. Gabriel D, Carr M, Roberts HR: Monitoring coagulation and the clinical effects of recombinant factor VIIa. Semin Hematol 41:20-24, 2003 (suppl 1)
7. Henderson N, Key NS, Christie B, et al: Response of factor VIII and IX-deficient blood to wild type and high membrane affinity mutant factor VIIa in an in vitro whole blood clotting assay: Possible correlation to clinical outcome. Thromb Haemost 88:98-103, 2002
8. Himmelspach M, Richter G, Muhr E, et al: A fully recombinant partial prothrombin complex effectively bypasses FVIII in vitro and in vivo. Thromb Haemost 88:1003-1011, 2002
9. Key NS, Christie B, Henderson N, et al: Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy. Thromb Haemost 88:60-65, 2002
10. Key NS, Christie BA, Jones B, et al: Evaluation of the in-vivo effect of rFVIIa (NovoSeven®) using the clot signature analyzer (CSA). Haemostasis 30:43a, 2000 (suppl, abstr)
11. Li CK, Hoffman TJ, Hsieh PY, et al: The Xylum Clot Signature Analyzer: A dynamic flow system that simulates vascular injury. Thromb Res 92:S67-77, 1998 (suppl)
12. Lisman T, Mosnier LO, Lambert T, et al: Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood 99:175-179, 2002
13. Lisman T, Leebeek FW, Meijer K, et al: Recombinant factor VIIa improves clot formation but not fibrinolytic potential in patients with cirrhosis and during liver transplantation. Hepatology 35:616-621, 2002
14. Melton LG, Thompson CM, Ezban M, et al: Dose response of rFVIIa concentrate on hemostasis in hemophilia. Blood 10:228a, 1999 (suppl, abstr)
15. Monroe DM, Hoffman M, Oliver JA, et al: Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 99:542-547, 1997
16. Monroe DM, Hoffman M, Roberts HR: Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 22:1381-1389, 2002
17. Nelsestuen GL, Stone M, Martinez MB, et al: Elevated function of blood clotting factor VIIa mutants that have enhanced affinity for membranes. Behavior in a diffusion-limited reaction. J Biol Chem 276:39825-39831, 2001
18. Parameswaran R, Shapiro AD, Gill JC, et al: Dose effect and efficacy of recombinant factor VIIa in the treatment of hemophilia patients with inhibitors: Analysis from the Hemophilia Research Society Registry. Blood 100:22a, 2002 (suppl, abstr)
19. Santagostino E, Morfini M, Rocino A, et al: Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haemost 86:954-958, 2001
20. Shah AM, Kisiel W, Foster DC, et al: Manipulation of the membrane binding site of vitamin K-dependent proteins: Enhanced biological function of human factor VII. Proc Natl Acad Sci USA 95:4229-4234, 1998
21. Sorensen B, Johansen P, Christiansen K, et al: Whole blood coagulation thromboelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 1:551-558, 2003
22. Sumner WT, Monroe DM, Hoffman M: Variability in platelet procoagulant activity in healthy volunteers. Thromb Res 81:533-543, 1996
23. Tranholm M, Kristensen K, Kristensen AT, et al: Improved hemostasis with superactive analogues of factor VIIa in a mouse model of hemophilia. Blood 102:3615-3620, 2003
24. Turecek PL, Varadi K, Keil B, et al: Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb 33:16-22, 2003